Back to INSMView Full Landscape
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
39 competitors in Cystic Fibrosis
ARCTARCT-032
VRTXTezacaftor/Ivacaftor
Phase 3VRTXELX/TEZ/IVA
Phase 3VRTXLUM/IVA
Phase 3VRTXTEZ/IVA
Phase 3Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA10/27/2020
Arikayce liposomal
Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.
Orphan
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
